Inside USP: A Holistic Approach to Supply-Chain Integrity - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside USP: A Holistic Approach to Supply-Chain Integrity
US Pharmacopeia documents best supply-chain practices and seeks broad input on proposal.


Pharmaceutical Technology
Volume 36, Issue 3, pp. 80-82

USP's role in supply-chain integrity

There has been much discussion in the industry regarding the challenges posed by a global supply chain, and yet, there are no overarching, comprehensive industry-wide practices to date. What does exist is piecemeal, with pockets of information available through FDA guidance, trade organizations, and other sources. USP believes it can provide value as a convener of different stakeholders. The organization can bring disparate views together and help organize the prevailing thoughts, finding commonalities among all players. In addition, through its inclusion in USPNF—compendia widely recognized both domestically and internationally—recommendations put forth in a general chapter can have more weight than, for example, a technical report.

Finally, with USPNF in a continuous state of revision, a mechanism exists for consistently updating the recommendations to reflect current realities. Because change is constant, USP's Expert Committee will be charged with monitoring whether there is a need for adapting the general chapter, thereby providing all parties with one central place for up-to-date information.

Industry participation

Given the complexity of this topic, USP is seeking extensive input from all the parties that have an interest in the new general chapter <1083>. Although the expert committee responsible for the chapter represents a diverse group of manufacturers, pharmacists, and other experts, USP is seeking additional perspectives to assist in providing a strong final product. The draft general chapter being published this spring may be deemed too broad or too specific, or may evolve into multiple chapters, for instance.

USP will evaluate all of these considerations based on feedback received from the diverse stakeholder community. In addition to comments obtained via the PF, USP is planning a Supply Chain Integrity Workshop at its headquarters in Rockville, MD, on May 22-23, 2012, to further solicit input. The workshop will seek to clarify USP's role in supply-chain integrity and address key topics such as related regulation and technology, and the roles and responsibilities of all parties in the supply chain. The workshop will have a strong international component as well.

Anthony DeStefano, PhD, is vice-president of general chapters, and Desmond Hunt, PhD, is a senior scientific liaison, both at the US Pharmacopeial Convention (USP).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here